Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Ollin-Biosciences"

2 News Found

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
Clinical Trials | January 11, 2026

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial

DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases


Innovent Biologics’ OLN324 shows breakthrough results in vision disease study
Biopharma | April 05, 2026

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred